Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients With Relapsed or Refractory Large B-Cell Lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 17
页数：3
相关论文
共 50 条
  • [21] Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR-T Consortium
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 14 - 15
  • [22] Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
    Jain, Michael D.
    Jacobs, Miriam T.
    Nastoupil, Loretta J.
    Spiegel, Jay Y.
    Feng, Gao
    Lin, Yi
    Lunning, Matthew A.
    Dahiya, Saurabh
    Lekakis, Lazaros J.
    Reagan, Patrick M.
    Oluwole, Olalekan O.
    McGuirk, Joseph P.
    Deol, Abhinav
    Goy, Andre
    Hill, Brian T.
    Munoz, Javier
    Chavez, Julio
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Bennani, N. Nora
    Andreadis, Charalambos
    Sehgal, Alison R.
    Ghobadi, Armin
    Locke, Frederick L.
    BLOOD, 2019, 134
  • [23] OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE
    Ong, Shin Yeu
    Krisnadi, Cindy
    Wang, Samuel Sherng Young
    Chen, Yun Xin
    Seng, Michaela Su-fern
    Soh, Shui Yen
    Chan, Esther Hian Li
    Hwang, William Ying Khee
    Ho, Aloysius Yew Leng
    Lim, Francesca Lorraine Wei Inng
    BONE MARROW TRANSPLANTATION, 2024, 59 : 226 - 226
  • [24] Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma
    Frank, Matthew J.
    Hossain, Nasheed
    Bukhari, Ali
    Dean, Erin
    Spiegel, Jay Y.
    Claire, Gursharan K.
    Kirsch, Ilan M.
    Jacob, Allison P.
    Mullins, Chelsea D.
    Lee, Lik Wee
    Kong, Katherine A.
    Craig, Juliana
    Mackall, Crystal L.
    Rapoport, Aaron P.
    Dahiya, Saurabh
    Locke, Frederick L.
    Miklos, David B.
    BLOOD, 2019, 134
  • [25] Axicabtagene Ciloleucel CD19 CAR T-Cells for Relapsed/refractory Large b-cell Lymphoma: realworld Outcomes, Toxicity and Predictors of Response from a Prospective UK Cohort
    Sanderson, Robin
    Benjamin, Reuben
    Patten, Piers
    Potter, Victoria
    Yallup, Deborah
    Cuthill, Kirsty
    Stewart, Orla
    Pagliuca, Tony
    Krishnamurphy, Pramila
    Inam, Shafqat
    Shah, Mili
    Wong, Shu
    Hockings, Catherine
    Metaxa, Victoria
    Kuhnl, Andrea
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 234 - 235
  • [26] Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Lekakis, Lazaros J.
    Jacobson, Caron A.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Timmerman, John M.
    Kersten, Marie Jose
    Zheng, Yan
    Zhang, Teresa
    Nater, Jenny
    Shen, Rhine
    Miao, Harry
    Kim, Jenny J.
    Miklos, David B.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11): : 1065 - 1079
  • [27] FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
    Bouchkouj, Najat
    Kasamon, Yvette L.
    de Claro, R. Angelo
    George, Bindu
    Lin, Xue
    Lee, Shiowjen
    Blumenthal, Gideon M.
    Bryan, Wilson
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (06) : 1702 - 1708
  • [28] CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
    Wei, Guoqing
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Liu, Yandan
    Liang, Bin
    Wang, Xiujian
    Xu, Huijun
    Cui, Jiazhen
    Wu, Wenjun
    Zhao, Kui
    Nagler, Arnon
    Chang, Alex H.
    Hu, Yongxian
    Huang, He
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (09) : 1061 - 1070
  • [29] Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma
    Talha Badar
    Bryon D. Johnson
    Mehdi Hamadani
    Bone Marrow Transplantation, 2021, 56 : 683 - 685
  • [30] Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma
    Othman, Tamer
    Baird, John H.
    Pak, Stacy
    Mei, Matthew
    Herrera, Alex F.
    Mansour, Joshua
    Shouse, Geoffrey
    Sahebi, Firoozeh
    Spielberger, Ricardo
    Cai, Ji-Lian
    Farol, Leonardo
    Godfrey, James
    Kallam, Avyakta
    Phillips, Tycel
    Popplewell, Leslie
    Siddiqi, Tanya
    Forman, Stephen
    Budde, Lihua E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (01) : 368 - 372
12345